Ketoconazole (systemic) vs Brentuximab Vedotin

Interacting Drugs
Ketoconazole (systemic)
vs
Brentuximab Vedotin
Security Level
Minor, Monitor Therapy
Mechanism
Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.
Management
Monitor therapy

Subscribe for latest updates

Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Post Review about Ketoconazole (systemic) vs Brentuximab Vedotin